SPEXIS
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
SPEXIS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1996-01-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.spexisbio.com
Total Employee:
11+
Status:
Active
Contact:
41615671601
Email Addresses:
[email protected]
Total Funding:
94.97 M USD
Technology used in webpage:
Domain Not Resolving Euro SPF Microsoft Exchange Online Office 365 Mail Microsoft DNS
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-01 | EnBiotix | EnBiotix acquired by Spexis | N/A |
Investors List
SPRIM Global Investments
SPRIM Global Investments investment in Post-IPO Debt - Spexis
SPRIM Global Investments
SPRIM Global Investments investment in Post-IPO Equity - Spexis
SPRIM Global Investments
SPRIM Global Investments investment in Debt Financing - Spexis
CARB-X
CARB-X investment in Grant - Spexis
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Spexis
CARB-X
CARB-X investment in Grant - Spexis
CARB-X
CARB-X investment in Grant - Spexis
Repair Impact Fund
Repair Impact Fund investment in Post-IPO Equity - Spexis
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Spexis
New Medical Technologies
New Medical Technologies investment in Venture Round - Spexis
Official Site Inspections
http://www.spexisbio.com Semrush global rank: 4.92 M Semrush visits lastest month: 1.74 K
- Host name: s062.cyon.net
- IP address: 149.126.4.71
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Spexis"
Spexis – Delivering Continuous Hope for Rare Disease and Cancer …
And in many therapeutic indications such as solid tumors, hematologic malignancy and stem cell mobilization. Although a P3 trial in metastatic breast cancer read out negatively in mid-2021, …See details»
About Spexis – Spexis
Who we are. Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer.The most advanced of …See details»
Spexis AG - Swiss Biotech
Spexis AG (SIX:SPEX) is a clinical-stage biotech company focused on first-in-class macrocyclic drugs for cancer & rare diseases. >25 years and $400M of …See details»
Spexis - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Spexis AG - LinkedIn
Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options …See details»
Spexis AG (SWX:SPEX) Company Profile & Description - Stock …
Mar 19, 2025 Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer.See details»
Spexis - SPRIM Global Investments
New York. 545 West 25th Street, 20th Floor New York, NY, USA 10001See details»
Spexis Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
For further information please contact: For Investors: Muriel Fleming, Esq. Global Head of HR & acting Chief Financial Officer Spexis AG +41 61 567 1600 [email protected] For Media: Dr. …See details»
Spexis - Overview, News & Similar companies | ZoomInfo.com
Spexis contact info: Phone number: +41 615671600 Website: www.spexisbio.com What does Spexis do? Spexis is a company that specializes in the manufacturing of pharmaceuticals with …See details»
Spexis 2025 Company Profile: Stock Performance & Earnings
The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has …See details»
Spexis - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 23, 2025 Spexis - Developer of antibiotic therapeutics for the treatment of cancer and rare diseases. Raised funding over 2 rounds from 2 investors. Spexis has 780 competitors.See details»
Spexis AG | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Spexis Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Spexis has 5 employees at their 1 location. See insights on Spexis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Spexis CEO and Key Executive Team | Craft.co
Spexis's CEO & Chairman is Jeffrey D. Wager. Other executives include Stephan Wehselau, Chief Operating Officer; Dennis Ausiello, Vice Chairman and 5 others. See the full leadership …See details»
Corporate Presentation – Spexis
© 2025, Spexis Ltd., Hegenheimermattweg 125, 4123 Allschwil, Switzerland, T: +41 61 567 16 00, [email protected] – Disclaimer – Privacy Rules – DisclosureSee details»
Spexis - Crunchbase Company Profile & Funding
Spexis is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.See details»
Spexis AG – Funding, Valuation, Investors, News | Parsers VC
Jan 15, 2024 Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new …See details»
Annual Report 2021 - spexisbio.com
The Cystic Fibrosis Foundation the leading patient advocacy and philanthropic organization servicing the needs of CF patients and their caretakers worldwide - also participated in our …See details»
News – Spexis
Oct 9, 2023 Original-Research: Spexis AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Spexis AG Unternehmen: Spexis AG ISIN: …See details»
Spexis announces USD $2.5 million capital commitment to support …
Aug 14, 2023 ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics …See details»